RPRX CEO acquires 36,559 shares via Rule 16b-3 settlement

Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares.

Rhea-AI Filing Summary

Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares. On 11/05/2025, he acquired 36,559 shares at $0 (code A) pursuant to Rule 16b-3 in connection with the settlement of Equity Performance Awards.

Following the transaction, his direct beneficial ownership stands at 940,955 shares. He also reports indirect holdings through various entities, including 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust.

Insider Trade Summary

Grant/Award: 36,559 shares

Grant/Award 12 txns

Insider Legorreta Pablo G.

Role CEO, Chairman of the Board

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	36,559	$0.00	$0.00
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 940,955 shares (Direct); Class A Ordinary Shares — 1,040,410 shares (Indirect, By Legorreta Children 2002 Trust); Class A Ordinary Shares — 901,590 shares (Indirect, By GST-Exempt Legorreta 2012 Family Trust); Class A Ordinary Shares — 600,000 shares (Indirect, By Legorreta 2023 SR Trust); Class A Ordinary Shares — 460,139 shares (Indirect, By Legorreta Investments LLC); Class A Ordinary Shares — 292,190 shares (Indirect, By Tata MC 35 Ltd.); Class A Ordinary Shares — 123,310 shares (Indirect, By IRRA); Class A Ordinary Shares — 118,500 shares (Indirect, By SEP/IRA); Class A Ordinary Shares — 41,306 shares (Indirect, By GST-Exempt Legorreta 2020 Family Trust); Class A Ordinary Shares — 10,000 shares (Indirect, By Son); Class A Ordinary Shares — 10,000 shares (Indirect, By Daughter); Class A Ordinary Shares — 6,930 shares (Indirect, By Spouse)

Footnotes (1)

1. F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RPRX CEO Pablo G. Legorreta report on Form 4?

He reported an exempt acquisition of 36,559 Class A shares at $0 on 11/05/2025 under Rule 16b-3 tied to equity award settlement.

How many RPRX shares does Legorreta own directly after this transaction?

He directly owns 940,955 Class A shares following the reported transaction.

What was the reason for the $0 acquisition price?

The shares reflect settlement of Equity Performance Awards, reported as an exempt acquisition under Rule 16b-3.

Does Legorreta have indirect ownership in RPRX?

Yes. Indirect holdings include 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust, among others.

What transaction code was used for the acquisition?

Transaction code A (acquisition) was used for the 36,559 shares.

What roles does Legorreta hold at Royalty Pharma?

He is a Director and serves as CEO, Chairman of the Board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Legorreta Pablo G.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Chairman of the Board

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	11/05/2025		A		36,559	A(1)	$0	940,955	D
Class A Ordinary Shares								1,040,410	I	By Legorreta Children 2002 Trust
Class A Ordinary Shares								901,590	I	By GST-Exempt Legorreta 2012 Family Trust
Class A Ordinary Shares								600,000	I	By Legorreta 2023 SR Trust
Class A Ordinary Shares								460,139	I	By Legorreta Investments LLC
Class A Ordinary Shares								292,190	I	By Tata MC 35 Ltd.
Class A Ordinary Shares								123,310	I	By IRRA
Class A Ordinary Shares								118,500	I	By SEP/IRA
Class A Ordinary Shares								41,306	I	By GST-Exempt Legorreta 2020 Family Trust
Class A Ordinary Shares								10,000	I	By Son
Class A Ordinary Shares								10,000	I	By Daughter
Class A Ordinary Shares								6,930	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.